Insider Brief
- Tevogen Bio (Nasdaq: TVGN) continues to expand its intellectual property portfolio with new AI-driven patent filings, highlighting its commitment to leveraging machine learning for drug discovery, manufacturing, and oncology pipeline development, including targeting Human Papilloma Virus (HPV).
- The company launched Tevogen.AI in October 2023, partnered with Microsoft in May 2024 through the Microsoft for Startups program, and is advancing its ExacTcell™ technology for off-the-shelf, precision T cell therapies.
- Tevogen Bio’s AI initiatives aim to enhance patient access, reduce costs, and position the company as a leader in biopharma innovation, with further updates expected at the J.P. Morgan Healthcare Conference in January 2025.
PRESS RELEASE — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio.
- In October 2023, Tevogen Bio launched its artificial intelligence effort, Tevogen.AI with the explicit goal to expedite enhancement of drug discovery, development, manufacturing, distribution, and patient access not only for Tevogen Bio’s efforts but also for other biotech companies.
- Later that month, Tevogen Bio appointed Mittul Mehta, with over 20 years of diverse experience in IT including over 10 years in senior management roles, to head Tevogn.AI. His cross-industry experience includes stints at Jefferies, MetLife, and Microsoft where his achievements underscored his ability to align technology with business goals.
- In December 2023, Tevogen Bio filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO), which was later converted to a PCT. Additionally, in December 2024, the company filed a second provisional application to further advance its artificial intelligence initiatives.
- In May 2024, Tevogen Bio entered a partnership with Microsoft (Nasdaq: MSFT) through the Microsoft for Startups program and gained access to experts and resources from a world-leading AI company.
- In November 2024, a direct impact of artificial intelligence effort was felt when machine learning was utilized for target identification to address Human Papilloma Virus (HPV). This signaled the start of Tevogen Bio’s oncology treatment pipeline. “Our ExacTcellTM technology is adaptable and can create a spectrum of CTL products targeting a wide range of viruses, including HPV,” said Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen Bio.
- On December 16, 2024, the International Application PCT/US2024/060419 was filed. “The filing of this patent further establishes our commitment to greater patient accessibility and quicker innovation while decreasing operating cost,” said Mr. Mehta. “Our AI initiative not only aligns with our company’s mission but also positions us as a driving force for future advancements.” According to The McKinsey Global Institute, Generative AI could generate $60 billion to $110 billion annually in economic value for pharmaceutical and medtech companies.
“When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow,” said Tevogen Bio CEO Dr. Ryan Saadi, M.D., M.P.H. “We will provide additional updates about the company, including our AI effort, at the J.P. Morgan Healthcare Conference in January 2025.”
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
